Canada markets close in 5 hours 33 minutes
  • S&P/TSX

    20,476.79
    -67.32 (-0.33%)
     
  • S&P 500

    4,317.76
    -8.75 (-0.20%)
     
  • DOW

    34,001.76
    -159.02 (-0.47%)
     
  • CAD/USD

    0.7835
    -0.0017 (-0.22%)
     
  • CRUDE OIL

    88.24
    +1.63 (+1.88%)
     
  • BTC-CAD

    47,315.16
    -17.69 (-0.04%)
     
  • CMC Crypto 200

    839.38
    -3.08 (-0.37%)
     
  • GOLD FUTURES

    1,788.10
    -6.90 (-0.38%)
     
  • RUSSELL 2000

    1,919.05
    -12.24 (-0.63%)
     
  • 10-Yr Bond

    1.8050
    -0.0020 (-0.11%)
     
  • NASDAQ

    13,330.43
    -22.35 (-0.17%)
     
  • VOLATILITY

    31.26
    +0.77 (+2.53%)
     
  • FTSE

    7,454.32
    -99.99 (-1.32%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • CAD/EUR

    0.7027
    -0.0015 (-0.21%)
     

How Much Of Australian Pharmaceutical Industries Limited (ASX:API) Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • API.AX

If you want to know who really controls Australian Pharmaceutical Industries Limited (ASX:API), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that used to be publicly owned tend to have lower insider ownership.

Australian Pharmaceutical Industries is not a large company by global standards. It has a market capitalization of AU$722m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Australian Pharmaceutical Industries.

View our latest analysis for Australian Pharmaceutical Industries

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Australian Pharmaceutical Industries?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Australian Pharmaceutical Industries already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Australian Pharmaceutical Industries' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Australian Pharmaceutical Industries. The company's largest shareholder is Washington H. Soul Pattinson and Company Limited, with ownership of 19%. In comparison, the second and third largest shareholders hold about 6.2% and 3.6% of the stock.

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Australian Pharmaceutical Industries

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in Australian Pharmaceutical Industries Limited. It has a market capitalization of just AU$722m, and insiders have AU$9.2m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public collectively holds 60% of Australian Pharmaceutical Industries shares. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Public Company Ownership

Public companies currently own 19% of Australian Pharmaceutical Industries stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Australian Pharmaceutical Industries has 2 warning signs we think you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting